For the quarter ending 2026-03-31, ADCT made $20,851K in revenue. -$32,968K in net income. Net profit margin of -158.11%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue, net | 20,851 | 23,058 | 16,427 | 18,839 |
| Restructuring, impairment and other related costs | - | -348 | 377 | 13,091 |
| Cost of product sales | 3,615 | 1,699 | 1,202 | 836 |
| Research and development | 19,877 | 18,184 | 26,803 | 30,090 |
| Selling and marketing | 12,708 | 11,986 | 10,688 | 10,147 |
| General and administrative | 9,896 | 9,456 | 8,326 | 8,822 |
| Total operating expense | 46,096 | 40,977 | 47,396 | 62,986 |
| Loss from operations | -25,245 | -17,919 | -30,969 | -44,147 |
| Interest income | 1,994 | 2,352 | 2,470 | 1,934 |
| Deferred royalty obligation interest expense | 8,727 | 9,182 | 8,996 | - |
| Effective interest expense on senior secured term loan facility | - | 3,829* | - | - |
| Other interest expense | - | 3* | - | - |
| Effective interest expense on senior secured term loan facility | 3,622 | - | 4,396 | - |
| Interest expense | 12,349 | 13,014 | 13,392 | 12,997 |
| Other, net | 2,632 | 21,768 | 925 | -182 |
| Total other expense, net | -7,723 | 11,106 | -9,997 | -11,245 |
| Gain before income taxes | -32,968 | -6,813 | -40,966 | -55,392 |
| Income tax expense | 0 | -404 | 0 | 1,254 |
| Loss before equity in net losses of joint venture | - | -6,409 | -40,966 | -56,646 |
| Equity in net losses of joint venture | - | 0 | 0 | 0 |
| Net loss | -32,968 | -6,409 | -40,966 | -56,646 |
| Basic EPS | -0.21 | -0.042 | -0.3 | -0.5 |
| Diluted EPS | -0.21 | -0.042 | -0.3 | -0.5 |
| Basic Average Shares | 154,142,347 | 150,877,894 | 136,446,534 | 113,743,358 |
| Diluted Average Shares | 154,142,347 | 150,877,894 | 136,446,534 | 113,743,358 |
ADC Therapeutics SA (ADCT)
ADC Therapeutics SA (ADCT)